Anti-Human Epidermal Growth Factor Receptor (EGFR) (Clone F4) - Purified

Leinco Technologies
Product Code: LEI-E102
Product Group: Primary Antibodies
CodeSizePrice
LEI-E102-0.25mg0.25 mg£305.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: F4
Regulatory Status: RUO
Target Species: Human
Applications:
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Immunoprecipitation (IP)
  • Western Blot (WB)
Shipping:
Ambient
Storage:
This purified antibody is stable when stored at 2-8°C. Do not freeze.

Images

1 / 1

Further Information

Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
A peptide (residues 985 to 996 of human EGFR) coupled to keyhole limpet hemocyanin.
Long Description:
EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer - although there is some evidence that preformed inactive dimers may also exist before ligand binding. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers. Over expression of the EGF-receptor is a hallmark of squamous cell carcinomas.
Target:
EGFR

References

1. Berger, S. M. et al. (1987) J. of Pathology 152:297 2. Downward, J. et al. (1984) Nature 311:483 3. Gullick, W. J. et al. (1985) EMBO J. 4:2869 4. Gullick, W. J. et al. (1986) Cancer Research 46:285 5. Gullick, W. J. et al. (1991) Br. Med. Bulletin 47:87